Previous 10 | Next 10 |
PTC Therapeutics to Participate at 41st Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH PLAINFIELD, N.J. , Jan. 4, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will present a company overview at the 41 s...
New York, New York--(Newsfile Corp. - December 5, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of PTC Therapeutics, Inc. (NASDAQ: PTCT) breached their fiduciary duties to shareholders. The investigation concerns p...
Brazilian Regulatory Authority Grants Approval for Waylivra™ for Familial Partial Lipodystrophy PR Newswire - First global regulatory approval for treatment of this rare genetic disease - SOUTH PLAINFIELD, N.J. , Dec. 1, 2022 /PRNewswire/ -- PT...
Upstaza™ Gene Therapy Granted Marketing Authorization for AADC deficiency by UK's MHRA PR Newswire - Upstaza ™ is the first gene therapy infused directly into the brain for the treatment of AADC deficiency - - MHRA authorization follows recent E...
Summary The registration-directed phenylketonuria study results are anticipated by the end of the quarter. Management claims there are about 58,000 PKU patients globally that they can target by 2030. This is likely a lowball estimate by close to an order of magnitude. ...
PTC Therapeutics, Inc. (PTCT) Q3 2022 Results Conference Call October 27, 2022 04:30 PM ET Company Participants Kylie O'Keefe - SVP, Head of Global Commercial and Corporate Strategy Stuart Peltz - Chief Executive Officer Matthew Klein - Chief Operating Officer ...
PTC Therapeutics ( NASDAQ: PTCT ) on Thursday said it would receive up to $1B in funding from Blackstone ( NYSE: BX ) affiliates to support the development of its pipeline. Funds managed by Blackstone Life Sciences and Blackstone Credit will provide ...
PTC Therapeutics press release ( NASDAQ: PTCT ): Q3 GAAP EPS of -$1.53 misses by $0.24 . Revenue of $217.13M (+56.5% Y/Y) beats by $32.21M . 2022 DMD revenue guidance and low end of total revenue guidance increased. Strategic financing with Blackstone with ...
PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results PTC Therapeutics Provides a Corporate Update and Reports Third Quarter Financial Results PR Newswire - Total quarterly revenue of $217 million , representing 57% year-over-...
PTC Therapeutics Announces Strategic Financing Collaboration with Blackstone with up to $1 Billion in Funding PR Newswire - Blackstone investment accelerates innovative product pipeline - - PTC will leverage Blackstone's network and life sciences expertis...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....